immuno-oncology

Portage Biotech Inc. (PRTG) announced its continued listing compliance on the Nasdaq Capital Market, as confirmed by the Nasdaq. The immuno-oncology firm focuses on developing novel biologics to harness the immune system against cancer. This release contains forward-looking statements subject to risks and uncertainties, with actual results potentially differing from projections.